Literature DB >> 1425873

Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers.

A Kecskés1, P Jahn, H Wendt, L Lange, R K Kuhlmann.   

Abstract

Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although many corticosteroids are available today, there is still a need for highly potent compounds with minimal adverse effects. Methylprednisolone aceponate (MPA) has recently been synthesized. Its activity has been evaluated using the vasoconstrictor assay and the poison ivy test (rhus dermatitis) in 19/20 healthy volunteers of either sex. Comparable blanching was found with MPA in a cream vehicle, in an ointment and a fatty ointment. Vasoconstriction and suppression of experimentally-induced poison ivy contact dermatitis were dose-dependent in the concentration range 0.01% to 0.5% MPA. Concentrations of MPA of at least 0.05% were significantly active. Following the highest dose, blanching was close to the maximum which can be obtained. This finding, and the improvement of rhus dermatitis, suggest that MPA belongs to the highly potent local glucocorticosteroids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425873     DOI: 10.1007/bf01740663

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Comparative bio-availability of proprietary topical corticosteroid preparations; vasoconstrictor assays on thirty creams and gels.

Authors:  B W Barry; R Woodford
Journal:  Br J Dermatol       Date:  1974-09       Impact factor: 9.302

2.  Correlation of the vasoconstriction assay and clinical activity in psoriasis.

Authors:  R C Cornell; R B Stoughton
Journal:  Arch Dermatol       Date:  1985-01

3.  The clinical assessment of topical corticosteroid activity.

Authors:  L Wilson
Journal:  Br J Dermatol       Date:  1976-03       Impact factor: 9.302

4.  A separation of clinical from epidermal thinning effect in the topical glucocorticoid clobetasone butyrate.

Authors:  D V Stevanovic; L Wilson; C G Sparkes
Journal:  Br J Dermatol       Date:  1977-01       Impact factor: 9.302

5.  Proprietary hydrocortisone creams. Vasoconstrictor activities and bio-availabilities of six preparations.

Authors:  B W Barry; R Woodford
Journal:  Br J Dermatol       Date:  1976-10       Impact factor: 9.302

6.  Assay of topical corticosteroids. Efficacy of suppression of experimental Rhus dermatitis in humans.

Authors:  K H Kaidbey; A M Kligman
Journal:  Arch Dermatol       Date:  1976-06
  6 in total
  1 in total

Review 1.  Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.

Authors:  M Schäfer-Korting; M H Schmid; H C Korting
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.